Boris Sepesi, MD / Tina Cascone, MD, PhD - Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do

Go online to PeerView.com/FYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team?, This PeerView Candid Conversations & Clinical Consults educational activity, based on a recent live broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances and provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, importance of identifying patients with EGFR mutations in earlier disease settings, and role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Apply the latest evidence and recommendations to identify patients with early-stage NSCLC who would benefit from adjuvant EGFR-targeted therapy, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and integration of adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC.